Initial experience with prostatic urethral lift versus enucleation of the prostate: a retrospective comparative study

Author:

Obinata Daisuke,Uehara Rio,Hashimoto Sho,Nakahara Ken,Yoshizawa Tsuyoshi,Mochida Junichi,Yamaguchi Kenya,Takahashi Satoru

Abstract

Abstract Background This study aimed to assess initial results and patient characteristics of prostatic urethral lift (PUL) compared with those of bipolar transurethral enucleation of the prostate (TUEB) in the treatment of benign prostatic hyperplasia (BPH) in older patients. Methods This retrospective study was conducted at a single institution and involved 25 consecutive patients with BPH who underwent PUL between April 2022 and May 2023. Patient characteristics, operative details, and pre- and postoperative symptom scores were evaluated. The results were compared with those of a previously reported TUEB group (n = 55). Results The mean age of the patients in the PUL group was 74.6 years, and the mean prostate volume was 47.5 ml. The PUL procedure significantly improved urinary symptoms, particularly incomplete emptying (p = 0.041), intermittency (p = 0.005), and weak stream (p = 0.001). The PUL group had higher comorbidity scores (p = 0.048) and included older patients (p = 0.002) than the TUEB group. TUEB showed better improvements in some symptoms and maximum flow rate (p = 0.01) than PUL; however, PUL had a shorter operative time and fewer complications than TUEB (p < 0.001). Conclusion The initial results demonstrate the efficacy and safety of PUL in older patients with BPH. Despite TUEB showing better outcomes in certain aspects than PUL, PUL offers advantages such as shorter operative time and fewer complications. Therefore, PUL can be considered a viable option for high-risk older patients with BPH.

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Urology,Reproductive Medicine,General Medicine

Reference22 articles.

1. Collaborators GBDBPH. The global, regional, and national burden of Benign Prostatic Hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the global burden of Disease Study 2019. Lancet Healthy Longev. 2022;3(11):e754–76.

2. Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R, De Nunzio C, Schips L. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to Benign Prostatic Hyperplasia: population-based cohort study. Eur Urol. 2015;68(3):418–25.

3. Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, Rwabasonga B, Risk MC, Wilt TJ. Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to Benign Prostatic Hyperplasia: a systematic review and Meta-analysis. Eur Urol. 2017;71(4):570–81.

4. Mukai R, Shimada K, Suzuki T, Nakao S, Tanaka M, Matsumoto K, Yoshida Y, Goto F, Inoue M, Satake R, et al. Trends Associated with hemorrhoids in Japan: Data Mining of Medical Information datasets and the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data Japan. Biol Pharm Bull. 2020;43(12):1831–8.

5. Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC, Roehrborn CG. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH). BJU Int. 2011;108(1):82–8.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3